Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study.
Fujii H, Tsuchiya M, Watanabe D, Otsuka R, Hirate D, Takahashi K, Go M, Kudo T, Shimomura K, Ando Y, Tani S, Takahashi T, Hayashi K, Chin M, Matsunami N, Takahashi M, Hasegawa A, Uchida T, Hashimoto H, Kubo A, Matsuhashi N, Suzuki A, Nishimura J, Inui N, Iihara H. Fujii H, et al. Among authors: ando y. Support Care Cancer. 2024 Apr 17;32(5):291. doi: 10.1007/s00520-024-08498-z. Support Care Cancer. 2024. PMID: 38630197
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Ando Y, Hayashi T, Ito K, Suzuki E, Mine N, Miyamoto A, Oya M, Matsuda H, Isaji A, Nakanishi T, Imaizumi K, Shibata T, Okada T, Sakurai K, Naito K, Uyama I, Kawada K, Takahashi H, Yamada S. Ando Y, et al. Support Care Cancer. 2016 Feb;24(2):871-878. doi: 10.1007/s00520-015-2856-9. Epub 2015 Jul 25. Support Care Cancer. 2016. PMID: 26206077 Free PMC article. Clinical Trial.
Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.
Maeda A, Yoshida H, Inoue H, Ejiri M, Yamaguchi S, Kushihara H, Yamamoto Y, Ando Y, Sato Y, Tashiro Y, Hasegawa A, Takahara Y, Mizutani M, Oze I, Shimizu J. Maeda A, et al. Among authors: ando y. Ann Palliat Med. 2021 Mar;10(3):2699-2708. doi: 10.21037/apm-20-1784. Epub 2021 Feb 7. Ann Palliat Med. 2021. PMID: 33615803 Free article.
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H, Hayashi T, Murai S, Shiouchi H, Ando Y, Kumazawa S, Ito K, Ikeda Y, Matsuoka H, Maeda K, Kawada K, Yasuda K, Yamada S. Ohta H, et al. Among authors: ando y. Cancer Chemother Pharmacol. 2017 May;79(5):1021-1029. doi: 10.1007/s00280-017-3294-9. Epub 2017 Apr 8. Cancer Chemother Pharmacol. 2017. PMID: 28391355 Free PMC article.
The Influence of Intervening on the Pharmaceutical Consultation Targeting Outpatients with Advanced Non-small Cell Lung Cancer Receiving Erlotinib Treatment.
Nishibe-Toyosato S, Ando Y, Goto Y, Hayashi T, Ito K, Matsuda H, Tsujii N, Tsuge M, Kawada K, Imaizumi K, Yamada S. Nishibe-Toyosato S, et al. Among authors: ando y. Biol Pharm Bull. 2021 Sep 1;44(9):1280-1285. doi: 10.1248/bpb.b21-00167. Epub 2021 Jun 22. Biol Pharm Bull. 2021. PMID: 34162777 Free article. Clinical Trial.
Effect of renal function on pemetrexed-induced haematotoxicity.
Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, Yamaguchi T, Funatsu M, Ikeda Y, Imaizumi K, Kawada K, Yasuda K, Yamada S. Ando Y, et al. Cancer Chemother Pharmacol. 2016 Jul;78(1):183-9. doi: 10.1007/s00280-016-3078-7. Epub 2016 Jun 10. Cancer Chemother Pharmacol. 2016. PMID: 27286996 Free PMC article.
2,769 results